These findings underscore the potential of PROTAC technology in developing innovative therapeutic strategies for autoimmune diseases and highlight the importance of degraders targeting key signaling molecules like BTK in modulating immune responses and alleviating disease symptoms. The gene discussed is BTK; the disease is autoimmune disease.